DelphX Announces Non-Brokered Unit Private Placement

Rhea-AI Summary

DelphX (OTCQB: DPXCF, TSXV: DELX) announced a non-brokered private placement of up to 3,000,000 units at C$0.05 per unit for gross proceeds of C$150,000. Each Unit comprises one common share and one warrant exercisable at $0.08 for two years. Completion is subject to TSX Venture Exchange approval and securities will carry a 4-month plus one day hold period. Insiders may participate subject to insider trading policy. Net proceeds are intended for working capital and corporate overhead.

Positive

• Raises up to C$150,000 for working capital
• Includes 2-year warrants potentially unlocking future capital

Negative

• Issues up to 3,000,000 new shares causing dilution
• Offering price of C$0.05 implies limited immediate capital

Toronto, Ontario--(Newsfile Corp. - January 22, 2026) - DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB: DPXCF) ("DelphX"), a leader in the development of new classes of structured products, announces that it intends to proceed with a non-brokered private placement ("the Offering") of up to 3,000,000 units (the "Units") at a subscription price of C$0.05 per Unit, for gross proceeds of C$150,000. Each Unit will consist of one common share ("Common Share") and one Common Share purchase warrant ("Warrant"). Each Warrant will entitle the holder to purchase one Common Share at a price of $0.08, for a period of two years from the date of issuance.

Completion of the Offering is subject to the approval of the TSX Venture Exchange. The securities issued pursuant to the Offering will be subject to a hold period of four months plus one day from the date of issuance. DelphX insiders may participate in the Offering, subject to compliance with DelphX's insider trading policy.

DelphX intends to use the net proceeds from the Offering in connection with working capital/corporate overhead.

About DelphX Capital Markets Inc.

DelphX is a technology and financial services company focused on developing and distributing the next generation of structured products. Through its special purpose vehicle Quantem LLC, the Company enables broker dealers to offer new private placement securities that provide for both fixed income and cryptocurrency solutions. The new DelphX securities will enable dealers and their qualified institutional investors (QIBs) accounts to competitively structure, sell and make markets in:

• Collateralized put options (CPOs) that provide secured rating downgrade protection for underlying corporate bonds and/or protection from losses in cryptocurrency holdings;

• Collateralized reference notes (CRNs) that enable investors to take on a capped rating downgrade and/or cryptocurrency loss exposure of an underlying security or cryptocurrency in exchange for attractive returns.

All CPOs and CRNs are fully collateralized and held in custody by US Bank. CPOs and CRNs are proprietary products created and owned by DelphX Capital Markets.

For more information about DelphX, please visit www.delphx.com.

George Wentworth, General Manager
DelphX Capital Markets Inc.
george.wentworth@delphx.com
(718) 509-2160

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281352

FAQ

What are the terms of DelphX's January 2026 private placement (DPXCF)?

Up to 3,000,000 units at C$0.05 each for gross proceeds of C$150,000; each unit includes one share and one warrant exercisable at $0.08 for two years.

How will DelphX (DPXCF) use the proceeds from the Offering?

DelphX intends to use net proceeds for working capital and corporate overhead.

Do DelphX insiders participate in the DPXCF private placement?

Insiders may participate subject to compliance with DelphX's insider trading policy.

What approvals are required to complete DelphX's non-brokered private placement (DPXCF)?

Completion is subject to approval by the TSX Venture Exchange and issued securities carry a 4-month-plus-one-day hold period.

What are the dilution and warrant impacts for DelphX shareholders from the Offering?

The Offering could add up to 3,000,000 shares plus warrants exercisable at $0.08, representing a direct dilution risk to existing shareholders.